Biosimilar Market Update - Biocon Biologics LTD and Samsung Bioepis

Goodwin
Contact

Goodwin

Last week, Biocon Ltd announced the approval of approximately a 150 million USD capital injection from Goldman Sachs.  Dr. Christian Hamacher, CEO, Biocon Biologics, said, “This capital injection by Goldman Sachs will enable us to make prudent investments in R&D, high-quality manufacturing, as well as, establish a global commercial footprint.”  As we reported late last month, Biocon reported increased year-over-year revenue of 10% to $17.6 billion and 11% growth in biosimilars to 6.07 billion and has emphasized commercialization of its Insulin Glargine product, Semglee®, in the U.S. during the past quarter.

Also, earlier this week, Samsung Bioepic announced that it has initiated a Phase 1 clinical trial for its proposed biosimilar to Prolia® (denosumab).  Prolia, marketed and sold by Amgen, is a treatment for glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture.  The announcement stated that the Phase 1 clinical trial for SB16 (denosumab) is a comparison between SB16 and Prolia in healthy male volunteers.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.